Senescent cells, which accumulate in the body as we age, can have detrimental effects on our health. The immune system’s ability to clear these cells diminishes over time, leading to age-related diseases. Senolytic therapies are emerging as a promising solution to selectively destroy senescent cells. First generation senolytic drugs like dasatinib and navitoclax have shown impressive results in reversing age-related diseases in mice. However, second generation senolytics are being developed to be more selective, have fewer side effects, and target a wider range of senescent cell types. Companies and research groups are actively working on new molecules, engineered immune cells, and gene therapy to eliminate senescent cells. With promising programs under development, it is expected that a more diverse range of options will be available for patients in the near future.
Lurking throughout your body are senescent cells, which resist death and release harmful biological signals as we age. Researchers have been exploring senolytics to selectively destroy these cells, with promising results in animal studies and human trials. New drugs and repurposed compounds are being tested to combat age-related conditions such as Alzheimer’s and kidney disease. Unity Biotechnology and other companies are developing drugs to target senescent cells and improve health outcomes. Additionally, immune cell therapies and gene therapy are being investigated as innovative approaches to eliminate senescent cells. Progress in this field offers hope for the future of aging research and treatment.
